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Abstract
 
B cell terminal differentiation involves development into an antibody-secreting plasma cell, reflect-
ing the concerted activation of proplasma cell transcriptional regulators, such as Blimp-1, IRF-4,
and Xbp-1. Here, we show that the microphthalmia-associated transcription factor (Mitf) is
highly expressed in naive B cells, where it antagonizes the process of terminal differentiation
through the repression of IRF-4. Defective Mitf activity results in spontaneous B cell activation,
antibody secretion, and autoantibody production. Conversely, ectopic Mitf expression suppresses
the expression of IRF-4, the plasma cell marker CD138, and antibody secretion. Thus, Mitf
regulates B cell homeostasis by suppressing the antibody-secreting fate.
Key words: autoimmunity • antibody secretion • cellular differentiation • 
immunoglobulin • IRF-4
 
Introduction
 
Terminal differentiation of B cells into plasma cells requires
at least three transcription factors (Blimp-1, IRF-4 and
Xbp-1) and involves the simultaneous acquisition of a capacity
for antibody secretion as well as an inhibition of class
switching, somatic hypermutation, and cell cycle progression
(1). During the germinal center reaction, other transcription
factors, including bcl-6 or Pax5, antagonize this process,
likely to allow for affinity maturation and isotype switching
before terminal differentiation. However, whether or not
these developmental processes are regulated in naive B cells
remains largely undetermined.
The microphthalmia-associated transcription factor (Mitf)
is a basic-helix-loop-helix-leucine-zipper protein that has
been primarily studied for its critical role in melanocyte
function, where it regulates the expression of essential pig-
ment enzymes (2). Its importance in cellular differentiation
likely further extends to multiple areas of cellular prolifera-
tion and viability because it also regulates expression of
antiapoptotic proteins such as bcl-2, at least in melanocytes
(3), and plays a role in the development and function of
mast cells, natural killer cells, and osteoclasts (4, 5). Previous
studies in 
 
mi/mi
 
 mice, which are functionally Mitf-deficient
due to a functionally disabling 
 
 
 
Arg mutation in their
DNA binding domain (6, 7), have suggested that dysfunc-
tional Mitf activity results in defective B cell development
(4, 5). However, given the osteopetrotic phenotype and
multiple other anatomical abnormalities of 
 
mi/mi
 
 animals, it
is difficult to discern whether or not their apparently di-
minished B cell numbers in the marrow and spleen indeed
reflects a B cell–intrinsic role for Mitf. Nonetheless, it is
tempting to speculate on a role for Mitf in B cells because a
review of microarray data in resting and activated B cells
suggests that it is highly expressed in resting cells and rap-
idly diminished in activated cells, suggesting a role in the
regulation of B cell activation (references 8, 9, and unpub-
lished data).
Here, we demonstrate that Mitf plays a critical role in
the maintenance of the mature, resting B cell state. Dys-
function of Mitf appears to result in spontaneous differenti-
ation of B cells into plasma cells, as well as autoantibody
production. Enforced expression of Mitf in activated B cells
represses the plasmacytoid phenotype, suppressing Ig secre-
tion and correlating with the ability of Mitf to repress IRF-4.
Thus, Mitf suppresses the antibody-secreting cell fate.
 
Materials and Methods
 
Mice. 
 
B6C3Fe 
 
a/a-Mitf
 
Mi
 
/J, Rag-2-deficient, and wild-type
C57BL/6J mice were obtained from The Jackson Laboratory. To
generate wild-type versus 
 
mi/mi
 
 animals, 
 
Mitf
 
Mi/
 
 
 
 animals were
intercrossed and genotyped by PCR on tail DNA using primers
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5
 
 
 
-GTCCTGGCTGGTGACGTCAGTACG-3
 
 
 
 and 5
 
 
 
-ACCTA-
GCTCCTTAATGCGGTCGTTTATG-3
 
 
 
, which span the 
 
 
 
Arg
of the 
 
mi
 
 mutation (6); sequencing of the product unequivocally
distinguished genotype (see Fig. 1 F). For chimeras, bone marrow
cells from day 0 newborn wild type versus 
 
mi/mi
 
 animals were
adoptively transferred intravenously to six Gy-irradiated Rag-2–
deficient recipients. Animals were analyzed 6–12 wk after re-
constitution. Immunizations and antihapten responses were
performed and determined as described previously (10). All ex-
periments were performed in compliance with the relevant laws
and institutional guidelines of the Washington University School
of Medicine.
 
Mitf Plasmids and Retroviruses. 
 
To isolate murine Mitf-M,
cDNA from a C57BL/6 day 14 embryo was amplified by PCR
using primers 5
 
 
 
-CTTGGGGCTGCCTGAAACCTTG-3
 
 
 
 and
5
 
 
 
-TGAATGAAAACGGACAGACACTTACTTC-3
 
 
 
. A single
 
 
 
1.6-kb fragment was obtained that was ligated to pCR2.1-
TOPO (Invitrogen), generating plasmid pMitf-M. To generate
Mitf-A, cDNA from a C57BL/6 day 14 embryo was amplified
by PCR using primers 5
 
 
 
-CCCCCATCTTTCTCAGGTGC-
CCG-3
 
 
 
 and 5
 
 
 
-GCCGGATCCATCAAGCCCAAAAT-3
 
 
 
.
The 812-bp product was ligated to pCR2.1-TOPO, and an
XhoI–XhoI fragment from this vector, corresponding to some
vector sequence, exon 1a, exon 1b, and part of exon 2 of the de-
duced Mitf-A isoform, was used to replace the corresponding
XhoI–XhoI fragment of pMitf-M, generating pMitf-A. Identi-
ties of both clones were confirmed by sequencing. To generate
Mitf expression vectors, the EcoRI–EcoRI fragments of pMitf-A
and pMitf-M containing their respective coding sequences
were ligated to the EcoRI site of pcDNA3 (Invitrogen), gener-
ating pcDNA3-Mitf-A and pcDNA3-Mitf-M, respectively. For
retroviral constructs, the same EcoRI–EcoRI fragments were li-
gated into the EcoRI site of pMX-IRES–green fluorescence
protein (GFP; reference 11), generating pMX-Mitf-A-IRES-
GFP and pMX-Mitf-M-IRES-GFP, respectively. Retroviral su-
pernatants were generated in the PlatE packaging line (11), and
transductions of murine B cells were performed as described
previously (12).
 
Rapid Amplification of cDNA Ends (RACE). 
 
To identify the
5
 
 
 
 sequence of Mitf-A, RNA was combined from purified naive
T and B cells of wild-type C57BL/6 mice and was subjected to
the SMART RACE cDNA amplification kit (CLONTECH
Laboratories, Inc.) with the reverse primer 5
 
 
 
-AGGCCCTGGT-
TGCTGTAGAG-3
 
 
 
, which is located in exon 2 (see Fig. 1 A).
Sequencing of the PCR product and comparison with the Na-
tional Center for Biotechnology Information murine genomic
sequence allowed the determination of the expressed exons.
 
Lymphocyte Purification, Culture, and Analyses. 
 
Naive-
enriched B cells were purified from spleens by negative selection
against CD43 (12). Results comparable to those shown in this pa-
per were obtained with B cells purified by negative selection
against both CD43 and CD5 (unpublished data). For in vitro dif-
ferentiation assays, B cells were further purified over a discontin-
uous Percoll gradient (70/66/60/50%) with resting B cells iso-
lated from the 66–70 interface. Cells were cultured in RPMI
1640 medium supplemented with 10% FCS (BioWhittaker) and
100 U penicillin/streptomycin (Sigma-Aldrich) in the presence
or absence of 25 
 
 
 
g/ml LPS (Sigma-Aldrich), 2 
 
 
 
g/ml anti-
CD40 antibody (BD Biosciences), 5–10 
 
 
 
g/ml anti-IgM (Jack-
son Immunologicals), 3 mM CpG-1 stimulatory phosphoro-
thioate oligonucleotide 5
 
 
 
-TCCATGACGTTCCTGACGTT-3
 
 
 
,
10,000 U/ml IFN-A/D (R&D Systems), 2 ng/ml APRIL, 100
ng/ml IFN-
 
 
 
, 5 ng/ml TGF-
 
 
 
, 100 U/ml hIL-2, 10 ng/ml IL-4,
500 ng/ml IL-5, 100 ng/ml IL-6, 5 ng/ml IL-7, 5 ng/ml IL-9,
10 ng/ml IL-10, 10 ng/ml IL-12, 5 ng/ml IL-13, 20 ng/ml IL-
15, and/or 25 ng/ml IL-18 (PeproTech). Where indicated, cells
were supplemented with 10 
 
 
 
M antisense IRF-4, 5
 
 
 
-GCTGC-
CCGTCTCCAAGTTCAT-3
 
 
 
, or missense oligonucleotide, 5
 
 
 
-
CTCTTCTCCTCGTTTTTTTAC-3
 
 
 
 (Integrated DNA Tech-
nologies). This strategy was derived from an antisense strategy
used to inhibit chicken IRF-4 and resulted in a 75–80% reduc-
tion in IRF-4 mRNA under the indicated culture conditions
(reference 13 and unpublished data). Flow cytometric assays, as
well as assessments for Ig secretion, Ig titers, autoantibodies, and
cellular proliferation were performed as described previously (12,
14). Viability/cellular ATP content was assessed using the Cell
Titer-Glo assay (Promega).
 
Expression Analysis. 
 
Isoform-specific RT-PCR for Mitf was
performed using primers and conditions described previously
(15). For real-time PCR detection of Mitf-A, primers 5
 
 
 
-GGC-
CTTGCAAATGGCAAA-3
 
 
 
 and 5
 
 
 
-AGGCCCTGGTTGCTGT-
AGAG-3
 
 
 
 were used on samples analyzed by an ABI PRISM
 
®
 
7000 Sequence Detection System (Applied Biosystems) under
standard conditions with specificity reinforced via the dissociation
protocol. Other gene-specific primers, including those for IRF-4
(16), have been described previously. Relative mRNA abun-
dance of each transcript was normalized against tubulin as de-
scribed previously (10). Western blots used a polyclonal goat
anti-Mitf (C-17; Santa Cruz Biotechnology, Inc.).
 
Luciferase Assays. 
 
An IRF-4 promoter–luciferase construct
was generated by PCR from C57BL/6 tail DNA using primers
5
 
 
 
-GGGGTACCAATTCGTCGGTTTCATTCACCCAA-
CATG-3
 
 
 
 and 5
 
 
 
-GAAGATCTACACTCCTCCTTCTGC-
CCGACTACAG-3
 
 
 
, which created a KpnI–BglII fragment
containing basepairs 
 
 
 
633 to 
 
 
 
71 (relative to the transcrip-
tional start site) of the IRF-4 promoter (17) that could be li-
gated into the KpnI–BglII sites of TK-luc (14). Sequences were
confirmed by routine sequencing. Derivatives with mutant pu-
tative Mitf binding sites (CANNTG) were generated by site-
directed mutagenesis (QuikChange
 
®
 
; Stratagene). For luciferase
activity assessment, 10
 
7
 
 M12 murine B cell lymphoma cells (12)
in 400 
 
 
 
l complete RPMI 1640 medium were electroporated in
a 0.4-cm cuvette at 280 mV, 975 
 
 
 
F in the presence of 10 
 
 
 
g of
luciferase reporter, 40 ng pRL-CMV, and 10 
 
 
 
g pcDNA3
(Invitrogen), pcDNA3-Mif-A, pcDNA3-Mitf-A(AS), or pcDNA3-
Mitf-M expression plasmids and returned to cell culture me-
dium. At the indicated times, reporter activity was determined
by the Dual-Luciferase
 
®
 
 Reporter Assay System (Promega); rel-
ative activity was determined after normalization for 
 
Renilla
 
luciferase.
 
ELISPOT Analyses. 
 
For quantification of antibody-secret-
ing cells, microtiter plates were coated with 10 
 
 
 
g/ml anti–
mouse Ig (Southern Biotechnology Associates, Inc.) in PBS and
blocked with 1% BSA. Single cell suspensions of splenocytes or
bone marrow cells were incubated in the plates with RPMI 1640
medium supplemented with 10% FCS, using limiting dilutions,
overnight at 37
 
 
 
C, 5% CO
 
2
 
. Bound antibody was detected with
IgM-, IgG1-, or IgG2b-specific alkaline phosphatase–conjugated
antibodies (Southern Biotechnology Associates, Inc.) followed
by development with 5-bromo,4-chloro,3-indolylphosphate
(Sigma-Aldrich) in 3% low-melt agarose. Spots were quantified
upon examination under a dissecting microscope.
 
Online Supplemental Material. 
 
Table S1 describes B cell pop-
ulations in native and chimeric 
 
mi
 
 mice. Online supplemental
material is available at http://www.jem.org/cgi/content/full/
jem.20040612/DC1. 
Lin et al. Brief Definitive Report
 
117
 
Results and Discussion
 
Identification and Characterization of Lymphoid Mitf (Mitf-L/
Mitf-A).
 
Ongoing microarray studies to identify novel reg-
ulatory transcription factors in B lymphocytes revealed a sig-
nificant signal from the 101159_at Affymetrix probe set by
resting but not activated B cell cDNA, corresponding to
Mitf (references 8, 9, and unpublished data). The expression
pattern of Mitf is tissue specific, with specific isoforms
formed by alternative promoter activity before distinct first
exons to produce melanocyte- (Mitf-M), mast cell– (Mitf-
MC), and heart-specific (Mitf-H) transcripts, among others
(Fig. 1 A); however, functionally relevant Mitf expression
has not been described previously in the lymphoid system.
Standard RT-PCR and Western blot analyses confirmed
expression of Mitf in B cells, particularly that its expression
is highest in resting, but not activated, cells (Fig. 1, B and
C). Interestingly, its expression could not be detected with
primers specific for the predominantly studied isoforms, but
only by primers within the common exons shared by all
known Mitf isoforms. Real-time PCR studies confirmed
these observations, demonstrating a suppression of Mitf ex-
pression in response to several stimuli, but most promi-
nently in response to polyclonal B cell activators such as
LPS or CpG oligonucleotides (Fig. 1 D).
Because the Mitf isoforms are only known to differ at the
5
 
 
 
 end due to alternative promoter use, 5
 
 
 
 RACE was per-
formed to identify the lymphocyte form (Mitf-L), producing
a dominant 
 
 
 
600-bp product (Fig. 1 E). Sequencing revealed
that the cDNA reflected the use of two Mitf exons previously
Figure 1. Expression characteristics of lymphoid Mitf (Mitf-L). (A) Genomic structure of the murine Mitf locus. Alternative use of the 1a and 1b exons,
in combination with the common exons 2–9, generates the Mitf-L isoform. Exon combinations for the melanocyte, heart, and mast cell–specific isoforms
consist of 1m (depicted), 1h–1b, and 1mc–1b, respectively, followed by exons 2–9. The location of the  Arg mutation in mi mice in exon 7 is indicated.
(B) RT-PCR analysis of Mitf expression in B cells. 100 ng cDNA from naive B cells treated with the indicated stimuli in vitro for 24 h was assessed for
Mitf expression using primers specific for the heart, melanocyte, and mast cell isoforms, or “common” primers that detect all Mitf isoforms (exons 2–3).
Control cDNA was generated from whole E14 murine embryo. White line indicates that intervening lanes have been spliced out. (C) Western analysis of
Mitf expression in B cells. 107 naive B cells were treated with the indicated stimuli in vitro for 24 h, and the whole cell lysate (equivalent to 107 originally
incubated cells) was subjected to Western blotting with anti-Mitf and antiactin antisera. (D) Real-time PCR analysis of Mitf in B cells. cDNA from naive
B cells treated with the indicated stimuli in vitro for 24 h was assessed for Mitf expression by real-time PCR. Error bars indicate standard deviations for
individually tested cells from three animals. (E) RACE product for the lymphoid isoform of Mitf. RACE was performed on wild-type B cell cDNA using
a reverse primer in Mitf exon 2. (F) Genotyping of mi animals. Tail DNA of representative animals was subjected to PCR with primers spanning exon 7.
Subsequent sequencing revealed unambiguous changes corresponding to the  AGA mutation of mi mice. Results are representative of at least three ex-
periments for each figure. 
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termed 1a and 1b (Fig. 1 A). Thus, Mitf-L uses exons 1a, 1b,
and the common exons 2–9; because this structure corre-
sponds to a previously described A isoform of Mitf (18), we
will use Mitf-A to refer to this species henceforth.
 
Mature B Cell Development Does Not Require Functional
Mitf.
 
To determine the role of Mitf in B cells, we exam-
ined 
 
mi/mi
 
 mice (Fig. 1 A and references 6, 7). Here, 
 
mi/mi
 
T cell development and function were largely normal, but
Figure 2. Hypergammaglobulinemia and plasma cell differentiation in the absence of functional Mitf. (A) Splenocytes from Rag-deficient animals
reconstituted 12 wk previously by bone marrow derived from wild-type or mi animals were analyzed by flow cytometry and gated on B220  or
B220 IgM  cells as indicated. Numbers indicate percentages of gated cells, and are representative of four to six animals of each genotype. Similar results
were seen when CD19 was used instead of B220 (not depicted). NFB/T1, new follicular B/T1 transitional; T2/F0, T2 transitional/follicular; MZ, mar-
ginal zone. (B) Sera from wild-type or mi Rag-deficient chimeras (n   5–7 in each group) were assessed for total Ig isotype concentrations, as well as
anti-DNA and rheumatoid factor autoantibodies. Horizontal bars indicate means. Dashed line indicates the threshold for positivity, as indicated by three
standard deviations above the mean OD of simultaneously assessed sera from wild-type C57BL/6 animals. (C) Spleens from wild-type or mi Rag-deficient
chimeras were analyzed by flow cytometry for plasma cells, CD38midCD138 CD5 B220 . CD138 versus CD38 plots after gating on CD5 B220  double
negative cells are shown. Numbers indicate percentages of the total splenocyte population, representative of three animals of each genotype. (D) Antibody-
secreting cells of the IgM and IgG1 isotypes were quantified in the spleen and bone marrow of wild-type or mi Rag-deficient chimeras by ELISPOT
analysis. Error bars indicate standard deviations for three individually tested animals of each genotype. 
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mi/mi
 
 animals possessed substantially fewer peripheral
B cells (reference 4, Table S1, available at http://www.
jem.org/cgi/content/full/jem.20040612/DC1, and un-
published data). However, because the impaired B cell
development could have resulted from the animals’ gener-
alized developmental delay (6, 7), we performed bone mar-
row chimerization from wt/wt versus 
 
mi/mi
 
 animals into
Rag-deficient recipients, confirming genotype by direct se-
quencing of the mutant region (Fig. 1 F). 
 
mi/mi
 
 bone mar-
row cells were clearly capable, surprisingly so, of fully re-
populating the B cell populations, both conventional and
B1 cells, as evidenced by largely normal flow cytometric
profiles for the various B cell subpopulations 8–12 wk after
reconstitution (Fig. 2 A and Table S1). Therefore, all sub-
sequent B cell analyses were performed with bone marrow
chimeric animals.
 
Hyperactivation of mi/mi B Cells.
 
Chimeric 
 
mi/mi
 
 ani-
mals developed hypergammaglobulinemia of the IgM but
not IgG1 isotype (Fig. 2 B, P 
 
  
 
0.0001). They also devel-
oped evidence of humoral autoimmunity, including anti-
DNA and rheumatoid factor (anti-IgG) activities (P 
 
 
 
0.0001 for all indicated specificities). However, these likely
represented largely nonpathogenic (e.g., anti-ssDNA) rather
than pathogenic (e.g., anti-dsDNA) autoantibody responses
because 
 
mi/mi
 
 sera were not reactive with the dsDNA-
containing kinetoplast of 
 
Crithidia luciliae
 
 substrates, nor was
there evidence of inflammation in the end-organs of 
 
mi/mi
 
chimeric animals (unpublished data).
Interestingly, chimeric 
 
mi/mi
 
 animals could mount IgM
and IgG antihapten responses comparable to their wild-type
counterparts when immunized with T-dependent (NP-
CGG or TNP-CGG) or T-independent (NP-Ficoll, TNP-
Ficoll, or TNP-LPS) antigens, indicating that mi B cells were
not hyperreactive per se (unpublished data). Such findings
suggested that mi/mi B cells simply undergo spontaneous ac-
tivation and/or differentiation into plasma cells in vivo,
without antigen-driven specificity. Indeed, mi/mi chimeras
contained increased numbers of CD138 B220  plasma cells
in their spleen, as well as IgM antibody-secreting cells in
their spleen and bone marrow (Fig. 2, C and D, P   0.01).
In vitro, naive mi/mi B cells spontaneously produced IgM in
the absence of external stimuli (Fig. 3 A, P   0.00001 for
both isotypes), albeit it was diminished in comparison to
LPS-stimulated B cells, and they spontaneously up-regulated
the plasma cell marker CD138 (syndecan-1) in culture (Fig.
3 B, P   0.0001 comparing mean fluorescence intensities at
2 d). At the same time, mi B cells proliferated less well than
their wild-type counterparts (Fig. 3 C, P   0.01 comparing
wild-type to mi at LPS concentrations of 10 and 25  g/ml),
but had increased intracellular metabolic activity, as judged
Figure 3. Spontaneous Ig se-
cretion by B cells in the absence
of functional Mitf. (A) Naive B
cells from wild-type or mi Rag-
deficient chimeras were incubated
in vitro in the presence or absence
of LPS, IL-4, and/or IFN- . After
10 d, supernatants were assessed
for Ig secretion by ELISA. Indi-
vidual data points represent B cells
obtained from individual mice
(n   3 for each genotype), with
means indicated by horizontal
bars. *, undetectable by assay ( 20
pg/ml). (B) Syndecan-1 (CD138)
expression was assessed on naive
B cells from wild-type or mi
Rag-deficient chimeras after 2 d
of incubation in culture without
mitogenic stimulation. (C) Pro-
liferation of naive B cells from
wild-type or mi Rag-deficient
chimeras was assessed by BrdU
incorporation on day 3 of stimu-
lation with the indicated con-
centrations of LPS. (D) Meta-
bolic activity of naive B cells
from wild-type or mi Rag-defi-
cient chimeras was assessed by
the CellTiter Glo assay for ATP
activity on the sixth day of treat-
ment with the indicated stimuli.
Error bars reflect standard devia-
tions from cells derived from
three individually tested animals.
These data are representative of
at least three separately per-
formed experiments.Mitf Suppresses Plasma Cell Development 120
by ATP activity (Fig. 3 D, P   0.01). These findings, such as
increased antibody secretory capacity, metabolic activity, and
CD138 expression despite diminished proliferative capacity,
are characteristic of plasma cell differentiation (1).
Suppression of B Cell Activation by Mitf via IRF-4. These
findings suggested that Mitf may enforce the naive B cell
state by suppressing plasma cell differentiation. Retroviral
transduction of Mitf-A into LPS-stimulated wild-type B
cells suppressed Ig secretion and CD138 expression (Fig. 4,
A and B): although control-transduced B cells secreted sig-
nificant levels of IgM over 2 d in culture, Mitf-A–trans-
duced B cells were largely unable to secrete Ig (P  
0.0001). Also, although  40–50% of control-transduced B
cells up-regulated CD138,  10% of Mitf-transduced B
cells did (P   0.0001). In addition, MHC class II expres-
sion remained higher in Mitf-transduced B cells (Fig. 4 B;
mean fluorescence intensity 662   43 vs. 853   23, com-
paring control- to Mitf-transduced cells, respectively; P  
0.001), which was consistent with a block in plasma cell
differentiation (1).
To gain insight into the potential mechanism by which
Mitf might regulate B cells, we sought to identify target
genes regulated by Mitf and, therefore, examined its ability
to regulate genes known to participate in plasma cell differ-
entiation. Interestingly, ectopic Mitf significantly sup-
pressed IRF-4 mRNA in LPS-stimulated B cells (Fig. 4 C,
P   0.0001), but not Blimp-1 or Xbp-1 (spliced or un-
spliced form; reference 19 and not depicted). Indeed, Mitf-A
could repress the activity of an IRF-4 promoter construct
in the M12 B cell lymphoma cell line (Fig. 4 D, P   0.001
comparing pcDNA to pcDNA-Mitf-A), and mi B cells ex-
pressed significantly elevated levels of IRF-4 (Fig. 4 E, P  
0.001). To test the importance of IRF-4 to the mi B cell
phenotype, we incubated B cells from mi chimeric animals
in culture medium without mitogens, but in the presence
or absence of an IRF-4 antisense oligonucleotide (Fig. 4 F).
Strikingly, the antisense oligonucleotide, but not a missense
control oligonuclotide, significantly reduced the sponta-
neous secretion of IgM (P   0.001 comparing no or mis-
sense to antisense oligonucleotide). Interestingly, although
Figure 4. Mitf represses plasma-
cytoid differentiation via IRF-4.
(A) B cells from wild-type
C57BL/6 animals were stimu-
lated with 25  g/ml LPS for 24
h and infected with a control
(pMX) or Mitf-A–expressing
(pMX-Mitf) GFP retrovirus in
the continued presence of LPS.
(A) On day 2 after infection,
GFP-positive cells were sorted
and returned to medium con-
taining LPS, and IgM secretion
was assessed 1 and 2 d thereafter
by ELISA. (B) On day 2 after in-
fection, cells were assessed for
syndecan-1 (CD138) and MHC
class II (I-A) expression by flow
cytometry. (C) GFP-sorted B
cells infected with a control or
Mitf-expressing retrovirus, as in
A, were returned to medium
containing LPS for an additional
24 h and assessed for the expres-
sion of IRF-4 by real-time
PCR. (D) The ability of Mitf to
regulate the IRF-4 promoter was
assessed by transient transfection
in M12 B cell lymphoma cells,
using a control, Mitf-A, or Mitf-A
antisense (AS) expression con-
struct. Firefly light units were
normalized against control Renilla
luciferase activity. (E) Naive B
cells from wild-type or mi Rag-
deficient chimeras were incu-
bated in vitro in the presence or
absence of LPS for 24 h. The ex-
pression of IRF-4 was assessed
by real-time PCR. (F) Naive B
cells from mi Rag-deficient chi-
meras were incubated in vitro without mitogenic stimulation in the presence or absence of IRF-4 antisense (AS) or missense (MS) oligonucleotides.
After 10 d, supernatants were assessed for IgM secretion by ELISA. Standard deviations reflect triplicate samples performed simultaneously, and are rep-
resentative of at least three experiments.Lin et al. Brief Definitive Report 121
the IRF-4 promoter contains two potential Mitf binding
sites (CANNTG) at basepairs  449 to  444 and  10 to
 4, mutagenesis of both sites failed to abrogate the ability
of Mitf to suppress our IRF4 promoter luciferase reporter
in M12 cells, and we have been unable to demonstrate
binding of Mitf to any portion of the IRF4 promoter by
electrophoretic mobility shift assays (unpublished data).
Thus, the effects of Mitf on B cell activation clearly require
IRF-4, but other genes likely cooperate with and/or are
regulated by Mitf to modulate IRF-4 expression.
Mitf in B Cell Development. As such, these data support
a model in which Mitf suppresses spontaneous plasma cell
differentiation in naive B cells by ultimately inhibiting the
expression of IRF-4. As a result, defective Mitf function
leads to IRF-4 overexpression and spontaneous plasma cell
differentiation, and is interestingly associated with mild hu-
moral autoimmunity. Therefore, defective Mitf activity may
contribute to diseases of humoral immune dysregulation,
such as autoimmune diseases (i.e., lupus). However, a Mitf
defect as a sole cause of such diseases seems unlikely; instead,
additional factors, such as T cell help (which is not accentu-
ated in mi animals), are probably required for full-blown
autoimmune disease (20). Nonetheless, a particularly in-
triguing finding in the present paper is the presence of IgG
anti-DNA autoantibodies in mi chimeric mice (Fig. 2), even
though Mitf primarily appears to affect IgM secretion (Figs.
2–4). Perhaps Mitf plays an additional role in the regulation
of autoreactive B cells, suppressing their activation and/or
subsequent differentiation, and/or enforcing tolerance.
In humans, mutations in Mitf result in the Waardenburg
syndrome (WS) type 2a, consisting of hypopigmentation
and deafness (for review see reference 2), but to our
knowledge, a humoral immune phenotype has not been
described in WS, and no mutations in Mitf have yet been
found to be associated with antibody-related disorders.
Nonetheless, Mitf resides on human chromosome 3 near a
known susceptibility locus for lupus (21), and increased
IRF-4 activity (22) and abnormal Wnt signaling (23),
which modulates Mitf activity (at least in melanocytes; ref-
erence 2), have both been observed in multiple myeloma.
Therefore, it will be of significant interest to perform a sys-
tematic study of antibody responses in WS patients, and to
determine if defective Mitf or overactive IRF-4 activity
contributes to the perturbed humoral immunity seen in
plasma cell dyscrasias or autoimmune diseases.
Interestingly, most functions of Mitf have been attributed
to its ability to transactivate target genes (24, 25), but it may
act as a transcriptional repressor upon interacting with other
transcription factors, such as Pax6 (26). Thus, it is possible
that Mitf regulates IRF-4 expression by interacting with
transcription factors, such as members of the NF- B or
NF-AT families, that can transactivate the IRF-4 promoter
(17), becoming a transcriptional repressor of IRF-4 itself.
However, the inability of Mitf to bind to the IRF-4 pro-
moter (unpublished data) suggests that Mitf instead either
represses the expression of a factor required to transactivate
IRF-4, or more likely transactivates a transcriptional repres-
sor of IRF-4. Regardless, our present findings strongly in-
dicate that active transcriptional repression of IRF-4 by
Mitf, via whatever means, is required to prevent spontane-
ous B cell activation, as well as tolerance loss. Therefore,
continued investigation into the mechanisms by which Mitf
regulates B cell activation and antibody production will un-
doubtedly shed insight into the mechanisms of immune tol-
erance and effector differentiation.
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